<DOC>
	<DOC>NCT00042601</DOC>
	<brief_summary>This is a single center, randomized, blinded, placebo-controlled, two-period, cross-over study to evaluate the effect of pramlintide on satiety and food intake in normal-weight and obese non-diabetic subjects and in insulin-treated subjects with type 1 and type 2 diabetes.</brief_summary>
	<brief_title>Evaluation of the Effect of Pramlintide on Satiety and Food Intake</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>For Healthy Volunteers: â€¢BMI &gt;=20 to &lt;=25kg/m2 or &gt;=30 to &lt;=40 kg/m2 For Subjects with Type 1 or Type 2 Diabetes: Treated with insulin for at least 6 months prior to screening HbA1c value between 6.510% inclusive BMI between 2040kg/m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>